O’Melveny Represents Pharmaron in US$171 Million New H-Share Placement
January 27, 2026
FOR IMMEDIATE RELEASE
SHANGHAI—January 27, 2026—O’Melveny represented Pharmaron Beijing Co., Ltd. (“Pharmaron”, 3759.HK) in its placing of 58,440,762 new H shares under general issuance mandate, at HK$22.82 per placing share. The gross proceeds from the placing is approximately HK$1.33 billion (approximately US$171 million). Goldman Sachs and HSBC acted as joint global coordinators, joint lead managers and joint bookrunners.
The placement was announced on January 14, 2026 and completed on January 22, 2026. Pharmaron disclosed that it will use the proceeds primarily for the enhancement of its laboratory services, drug process development, and manufacturing facilities.
O’Melveny previously represented Pharmaron in its Hong Kong IPO, as well as multiple of its cross-border acquisitions and financing transactions. Pharmaron is a leading fully integrated, end-to-end pharmaceutical R&D and manufacturing services platform that has established a successful global footprint.
The O’Melveny team was led by Shanghai corporate partners Portia Ku and Vincent Lin. The core team members included counsel Edward Poon, associate Ella Li and legal consultant Chris Wu. Trainee solicitor Bianca Cheng also made contributions.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com; learn more in our firm at-a-glance; and find us on LinkedIn, Facebook, Instagram, and YouTube.
Contact:
Brandon Jacobsen
O’Melveny & Myers LLP
+1 213 430 8024
bjacobsen@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com
# # #